Scarica l'app Stockscreener
19.38
2.43%
0.46
Dopo l'orario di chiusura:
19.25
-0.13
-0.67%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
What makes Summit Therapeutics (SMMT) one of the best large caps under $30 - MSN
Chart Watch: Whats next for Summit Therapeutics Inc stockEarnings Beat & Long-Term Growth Plans - baoquankhu1.vn
Revolution Medicines and Summit Therapeutics Advance Broad RAS(ON) Combo Study in Solid Tumors - TipRanks
We're Not Very Worried About Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Rate - Moomoo
Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab - MSN
Does Summit Therapeutics (SMMT) Expanding Ivonescimab Trials Clarify Its Single-Asset Oncology Strategy? - simplywall.st
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - AOL.com
(SMMT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Wells Fargo Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Summit plunges 80 percent after muscle-wasting disorder drug fails - AOL.com
SMMT Stock Price, Quote & Chart | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Assenagon Asset Management S.A. Invests $1.04 Million in Summit Therapeutics PLC $SMMT - MarketBeat
$Summit Therapeutics (SMMT.US)$ - moomoo.com
Summit Therapeutics PLC (NASDAQ:SMMT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Barclays Maintains Summit Therapeutics (SMMT) Underweight Recommendation - MSN
Barclays Remains a Hold on Summit Therapeutics (SMMT) - The Globe and Mail
Aug Retail: Is Summit Therapeutics Inc undervalued by DCF analysisGap Down & Weekly Sector Rotation Insights - baoquankhu1.vn
Barclays Maintains Summit Therapeutics(SMMT.US) With Hold Rating, Maintains Target Price $18 - Moomoo
Summit Therapeutics Links Ivonescimab Brain Metastases Data To November PDUFA - Sahm
Summit Therapeutics stock drops 3.94% as FDA accepts BLA for Ivonescimab in NSCLC - Traders Union
A Look At Summit Therapeutics (SMMT) Valuation After New Ivonescimab Phase III Data And FDA BLA Filing - finance.yahoo.com
Summit Therapeutics (SMMT) Is Up 6.9% After Phase III Ivonescimab Data And FDA FilingWhat's Changed - Yahoo Finance
Summit Therapeutics (SMMT) climbs 15.4% ahead of pipeline Q2 updates - msn.com
Summit Therapeutics outlines ivonescimab progress with key Phase III data expected mid-2025 - MSN
Summit Therapeutics to present ivonescimab data at ELCC 2026 - StreetInsider
Summit Therapeutics Inc. Announces Multiple Ivonescimab Data Sets from Phase III Studies in Advanced Nsclc Patient Populations to Be Featured At ELCC 2026 - marketscreener.com
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026 - Business Wire
Summit lung cancer drug showed 10.1-month brain PFS in Phase III - Stock Titan
Summit Therapeutics (NASDAQ:SMMT) Raised to Strong-Buy at Truist Financial - MarketBeat
What Makes Summit Therapeutics (SMMT) One of the Best Large Caps Under $30 - Insider Monkey
Aug Sectors: Can Summit Therapeutics Inc be the next market leader - baoquankhu1.vn
5 Large Cap Stocks Under $30 With Huge Upside Potential - Insider Monkey
Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates - Insider Monkey
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - The Motley Fool
U.S. Markets Rose Wednesday; Summit Therapeutics Topped Leaders - Barron's
Summit Therapeutics Enters Strong Growth Phase Amid Partnerships and Trials - StocksToTrade
Summit Therapeutics (NASDAQ:SMMT) Trading 12.1% HigherHere's What Happened - marketbeat.com
Summit Therapeutics Inc. (SMMT) focused on non-small cell lung cancer trial of Ivonescimab - MSN
Summit Therapeutics (SMMT) Stock Price Prediction for 2026, 2030-2040 - Traders Union
347,241 Shares in Summit Therapeutics PLC $SMMT Acquired by Tudor Investment Corp ET AL - marketbeat.com
Responsive Playbooks and the SMMT Inflection - Stock Traders Daily
Trade Recap: Does Summit Therapeutics Inc have a sustainable dividend2026 Investor Takeaways & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT) - The Globe and Mail
SMMT PE Ratio & Valuation, Is SMMT Overvalued - Intellectia AI
Summit Therapeutics Inc.Common Stock (NQ: SMMT - FinancialContent
Jefferies downgrades Summit Therapeutics (SMMT) - MSN
Should Jefferies’ Downgrade and Ivonesimab Focus Shape Summit Therapeutics’ (SMMT) Risk‑Reward Profile? - simplywall.st
SMMT Downgraded by Jefferies, Price Target Slashed by 64% | SMMT Stock News - GuruFocus
Summit Therapeutics (NASDAQ:SMMT) Rating Lowered to "Hold" at Jefferies Financial Group - MarketBeat
Summit Therapeutics downgraded to Hold from Buy at Jefferies - TipRanks
J&J files trade secret lawsuit against former oncology employee linked to Summit Therapeutics - Fierce Pharma
SMMT SEC FilingsSummit Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Summit Therapeutics (NASDAQ:SMMT) Trading 6.5% HigherTime to Buy? - MarketBeat
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):